Chronic Obstructive Pulmonary Disease (COPD)

Tiotropium Bromide and Olodaterol Labeling Updated With Revised Indication

Tiotropium Bromide and Olodaterol Labeling Updated With Revised Indication

By

The FDA has approved updated labeling for Stiolto Respimat to include COPD exacerbation data and a revised indication.

Hospital Readmissions Reduced for COPD With Discharge Care Bundle

Hospital Readmissions Reduced for COPD With Discharge Care Bundle

By

Patients who received a discharge care bundle after being hospitalized for an acute exacerbation of COPD had a lower rate of readmission.

Opioid Use Increases Likelihood of Intubation in COPD

Opioid Use Increases Likelihood of Intubation in COPD

By

Patients with chronic obstructive pulmonary disease who used opioids were more likely to be intubated during their hospitalization compared with nonopioid users

Beta-Blockers Safe in COPD With Cardiovascular Comorbidities

Beta-Blockers Safe in COPD With Cardiovascular Comorbidities

By

There was a trend toward a reduction in mortality in patients with COPD who received beta-blocker treatment compared with patients who did not.

Aclidinium Reduced Rate of COPD Exacerbations Regardless of CV Risk

Aclidinium Reduced Rate of COPD Exacerbations Regardless of CV Risk

By

Major cardiovascular adverse events were more common in the previous event subgroup, with 5.5% occurring in the aclidinium group and 6.2% in the placebo group.

Improved Exercise Capacity in COPD With Automatic Oxygen Titration

Improved Exercise Capacity in COPD With Automatic Oxygen Titration

By

Patients with severe COPD improved significantly in both endurance time and walking distance with the use of automatically titrated oxygen flow vs constant oxygen flow.

Prophylactic Antibiotics Reduce COPD Exacerbations in Stable Disease

Prophylactic Antibiotics Reduce COPD Exacerbations in Stable Disease

By

Treatment with prophylactic antibiotics was associated with a reduction in the frequency of COPD exacerbations and improved quality of life.

COPD, ILD Do Not Benefit More From Bilateral Transplantation Only Listing

COPD, ILD Do Not Benefit More From Bilateral Transplantation Only Listing

By

No meaningful associations were detected in procedural listing preferences and survival outcomes in patients with COPD or interstitial lung disease awaiting lung transplant.

Adipose Tissue Transfer, Lung Scaffolds: The Future of Stem Cells in COPD

Adipose Tissue Transfer, Lung Scaffolds: The Future of Stem Cells in COPD

By

Clinicians are eager for new therapies to address the damage to airways and lung parenchyma because no current therapy can completely reverse COPD damage.

Urban Training™ Efficacious in Increasing Physical Activity in COPD

Urban Training™ Efficacious in Increasing Physical Activity in COPD

By

After 12 months, patients in the Urban Training™ group had increased their number of daily steps by 816 compared with 64 steps in the usual care group.

RPL554 Combined With LABAs or LAMAs Increases Bronchodilation in COPD

RPL554 Combined With LABAs or LAMAs Increases Bronchodilation in COPD

By

Additional bronchodilation and hyperinflation reduction occurred in COPD when RPL554, an inhaled PDE 3 and 4 inhibitor, was combined with standard bronchodilators.

Climate Change: Dire Implications for Respiratory Conditions

Climate Change: Dire Implications for Respiratory Conditions

By

Changing pollination patterns, extreme weather events, rising sea levels, air pollution, and extreme temperatures all negatively affect respiratory conditions.

ICS/LABA Combined in One Inhaler vs LAMA Compared for Efficacy, Safety in COPD

ICS/LABA Combined in One Inhaler vs LAMA Compared for Efficacy, Safety in COPD

By

There were no statistically significant differences in mortality rates, rates of COPD exacerbations, lung inflammation, or serious adverse events between a once-daily combined inhaled corticosteroid/LABA and LAMA.

Combining COPD Screening and Community Drug Services Benefits Heroin Smokers

Combining COPD Screening and Community Drug Services Benefits Heroin Smokers

By

A total of 35% of heroin smokers screened positive for COPD.

Revefenacin Cuts COPD Exacerbation Rates in Phase 3 Studies

Revefenacin Cuts COPD Exacerbation Rates in Phase 3 Studies

By

Pooled data from two identical 12-week pivotal Phase 3 trials (N=1229) in patients with moderate to very severe COPD showed that the mean annualized rate of all COPD exacerbations was 0.47, 0.45, and 0.55 for revefenacin 175mcg/day, 88mcg/day, and placebo, respectively.

Small Reduction in Lung Function With Treatment De-Escalation in COPD

Small Reduction in Lung Function With Treatment De-Escalation in COPD

No difference in exacerbations with indacaterol/glycopyrronium for non-frequently exacerbating COPD.

New Bronchoscopic Option Used for Severe Emphysema

New Bronchoscopic Option Used for Severe Emphysema

First bronchoscopic lung volume reduction using endobronchial valve performed at Temple University in Philadelphia, PA.

FDA: More Data Required to Support Mepolizumab Approval for COPD

FDA: More Data Required to Support Mepolizumab Approval for COPD

By

In their Complete Response Letter, the FDA stated that they require more clinical data to support approval.

Tiotropium Associated With Increased Cardiovascular Risk in COPD

Tiotropium Associated With Increased Cardiovascular Risk in COPD

By

Cardiovascular risk within 30 days of therapy start was approximately 2-fold higher with the incident use of tiotropium in COPD.

COPD Has Altered Deposition of Inhaled Nanoparticles

COPD Has Altered Deposition of Inhaled Nanoparticles

By

In patients with emphysema, deposition fraction was significantly lower than in other individuals, but no significant differences were found between healthy never smokers and current or former smokers.

Skeletal Muscle Mass in COPD Improved With Bimagrumab

Skeletal Muscle Mass in COPD Improved With Bimagrumab

By

Thigh muscle volume showed significant improvements in patients with COPD who were treated with bimagrumab vs placebo.

Comorbidities Affect Treatment for COPD Exacerbations

Comorbidities Affect Treatment for COPD Exacerbations

By

Patients with COPD who have comorbidities are less likely to receive beneficial treatment for exacerbations.

COPD Screening Should Not Be Limited to Symptomatic Patients

COPD Screening Should Not Be Limited to Symptomatic Patients

By

The incidence of undiagnosed COPD was 26%, and based on the GOLD spirometry grading system, 95% had mild to moderate disease.

COPD Exacerbation Rates May Worsen During Colder Seasonal Temperatures

COPD Exacerbation Rates May Worsen During Colder Seasonal Temperatures

By

Although the summer season yielded the lowest overall COPD exacerbation rate, 43% of exacerbations during summer were moderate to very severe.

Bronchiectasis Prevalence on the Rise in COPD

Bronchiectasis Prevalence on the Rise in COPD

By

The average annual prevalence of bronchiectasis from 2012 to 2014 was 701 cases per 100,000 individuals.

Species-Specific Interactions of Common Bacteria in COPD

Species-Specific Interactions of Common Bacteria in COPD

By

S pneumoniae colonization was positively associated with H influenza colonization, whereas negative associations were reported between P aeruginosa and H influenzae and between P aeruginosa and M catarrhalis.

Asthma, COPD Readmissions Independently Predicted by Chronic Rhinitis

Asthma, COPD Readmissions Independently Predicted by Chronic Rhinitis

By

Comorbid chronic rhinitis is significantly associated with 30-day hospital readmissions related to asthma and chronic obstructive pulmonary disease.

<i>Pseudomonas</i> Associated With Frequent Hospitalizations Due to COPD Exacerbations

Pseudomonas Associated With Frequent Hospitalizations Due to COPD Exacerbations

By

Prior use of systemic corticosteroids and prior isolation of Pseudomonas aeruginosa were risk factors associated with the presence of Pseudomonas aeruginosa in COPD.

Hailie Solution Now Available for Tracking Asthma, COPD Medication Use

Hailie Solution Now Available for Tracking Asthma, COPD Medication Use

By

Through Bluetooth technology, clinicians and patients will be able to share and monitor inhaler usage.

Short-Term Corticosteroids Sufficient in Acute COPD Exacerbations

Short-Term Corticosteroids Sufficient in Acute COPD Exacerbations

By

Short-term corticosteroids may be sufficient for treating patients with acute COPD exacerbations.

Sign Up for Free e-newsletters